



## Orchestra BioMed to Present at Upcoming Investor Conferences

December 9, 2023

NEW HOPE, Pa., November 9, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple conferences throughout November and December.

Details on the presentations are shown below.

### ***Jefferies London Healthcare Conference***

**Format:** Corporate presentation

**Date:** November 14, 2023

**Time:** 7:00 AM ET

### ***Piper Sandler Healthcare Conference***

**Format:** Corporate presentation

**Date:** November 29, 2023

**Time:** 1:00 PM ET

**Webcast:** [https://event.webcasts.com/starthere.jsp?ei=1643548&tp\\_key=ddeef2541](https://event.webcasts.com/starthere.jsp?ei=1643548&tp_key=ddeef2541)

### ***Mizuho Med Devices Summit***

**Format:** 1x1 Meetings Only

**Date:** December 6, 2023

A live audio webcast of the presentation can be accessed through the [Investor Relations](#) section of the Company's website at <https://investors.orchestrabiomed.com/news-events/events>. An archived replay of the webcast will be available on the Company's website for 90 days following the live event.

### **About Orchestra BioMed**

Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed's partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed's flagship product candidates include atrioventricular interval modulation (AVIM) therapy (BackBeat CNT) for the treatment of hypertension, the leading risk factor for death worldwide, and Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic coronary artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed has additional product candidates and plans to potentially expand its product pipeline through acquisitions, strategic collaborations, licensing, and organic development. For further information about Orchestra BioMed, please visit [www.orchestrabiomed.com](http://www.orchestrabiomed.com), and follow us on [LinkedIn](#) and [X \(formerly Twitter\)](#).

References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

**Investor Contact:**

Bob Yedid  
LifeSci Advisors  
(646) 597-6989  
[Bob@lifesciadvisors.com](mailto:Bob@lifesciadvisors.com)

**Media Contact:**

Kelsey Kirk-Ellis  
Orchestra BioMed  
(484) 682-4892  
[kkirkellis@orchestrabiomed.com](mailto:kkirkellis@orchestrabiomed.com)